肺癌表皮生长因子受体突变与甲状腺转录因子-1表达的相关性探讨

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (500 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the relationship epidermal growth factor receptor (epidermal growth factor receptor, EGFR) mutation status and thyroid transcription factor-1 (thyroid transcription factor-1, TTF-1) between the expression and clinical pathological characteristics in the lung cancer. Methods From 40 patients of operatively resected lung cancer specimens were collected.Using amplification refractory pre system (ARMS) and polymerase chain reaction (PCR), mutation of EGFR gene in lung cancer tissue was detected. Histological typingwas according to the 2011 WHO classification operation specimens. The analysis of relationship between EGFR mutation and TTF-1 expression and clinical pathological characteristics in the lung cancers was analyzed using the statistical software of SPSS17.0. Results In 40 patients with lung cancer, EGFR gene mutation probability was 57.5% (23/40). EGFR gene mutation related to lung cancer patient’s sex, smoking history, lung cancer’s subtype and TTF-1 expression (P<0.05). Conclusions In lung cancer, EGFR gene mutation status is related to TTF-1 expression and histological type, gender, history of smoking. Thewomenwith strong expression of TTF-1,without smoking history and adeno-carcinoma patients have the higher EGFR mutation rate.

Key words： lung cancer epidermal growth factor receptor thyroid transcription factor-1 clinical characteristics

Received: 19 December 2014

ZTFLH:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAO Wenlian
	XU Xin

Cite this article:

YAO Wenlian,XU Xin. Association of EGFR mutation and TTF-1 and clinical characteristics in lung carcinoma[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(5): 455-457.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2015/V26/I5/455

[1]	Herbst R S,Heymach J V,Lippman S M. Lung cancer[J].N Engl J Med, 2008,359:1367-1380.
[2]	Jemal A,Bray F,Center M. Global cancer statistics,2011[J].CA Cancer J Clin,2011,61:69-90.
[3]	Sequist L V, Lynch T J. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story[J].Annu Rev Med,2008,59:429-442.
[4]	Burgess D J.Cancer genetics: initially complex, always heterogeneous[J].Nat Rev Cancer,2011,11:153.
[5]	Bunnell C A, Shulman L N. Will we be able to care for cancer patients in the future?[J].Oncology (Williston Park),2010,14:1343-1348.
[6]	Sharma S V, Bell D W, Settleman J,et al. Epidermal growth factor receptor mutations in lung cancer[J].Nat Rev Cancer,2007,7:169-181.
[7]	Lynch T J,Bell D W,Sordella R,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350:2129-2139.
[8]	Paez J G. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy[J].Science,2004,304:1497-1500.
[9]	Pao W,Miller V. EGFR receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib[J].Proc Natl Acad Sci USA,2004,101:13306-13311.
[10]	Yoshida T, Ishii G, Goto K, et al. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma[J].J Cancer Res Clin Oncol,2013,139(10):1691-1700.
[11]	Fukuoka M,Thongprasert S. Biomarker analyses and final overall survival results from a phase ⅡI, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)[J]. J Clin Oncol,2011,29:2866-2874.
[12]	Mok T S,WU Y L, Thongprasert S,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361:947-957.
[13]	KIM Y H,ISHⅡ G,GOTO K, et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung[J].Clin Cancer Res,2004,10:7311-7317.
[14]	李艳秋,刘杰,刘瑞青,等.肺腺癌组织学亚型与EGFR突变及临床特征的关系[J].西安交通大学学报(医学版),2014,35(1):94-98.
[15]	刘瑞青,申淑景.肺腺癌组织中TTF-1和SPA的表达对EGFR突变的临床预测价值[J].第三军医大学学报,2012,34(22):78-81.
[16]	Eberhard D A, Johnson B E, Amler L C. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J].J Clin Oncol,2005,25:5900-5909.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(8): 711-712.